| アブストラクト | BACKGROUND: Biologics for asthma and related conditions target distinct immunologic pathways but may have differential effects on glucose metabolism. Emerging real-world evidence suggests a need to evaluate potential associations with diabetes mellitus (DM) and related metabolic adverse events (AEs). OBJECTIVE: To assess the disproportionality of DM and other metabolic AEs associated with six biologics approved for asthma and related conditions using data from the FDA Adverse Event Reporting System (FAERS). METHODS: Reported odds ratios (RORs) were calculated for metabolic events and DM for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab, comparing drug-specific AE profiles against the FAERS background. RESULTS: Omalizumab (ROR: 6.10) and benralizumab (ROR: 4.88) exhibited significant disproportionality regarding diabetes AEs, with mepolizumab also demonstrating an elevated ROR (2.80). For metabolic AEs, mepolizumab (ROR: 3.57) and omalizumab (ROR: 2.94) had the highest signals. Dupilumab showed the lowest RORs for both diabetes (0.10) and metabolic AEs (0.21). CONCLUSION: This FAERS-based analysis identified a potential pharmacovigilance signal for DM associated with several biologics used to treat asthma and related conditions, most notably omalizumab and benralizumab. Similar patterns were observed for metabolic AEs, which reinforces the need for post-marketing studies and clinical awareness in patients with or at risk for metabolic disorders. |
|---|
| ジャーナル名 | Pulmonary pharmacology & therapeutics |
|---|
| Pubmed追加日 | 2025/7/5 |
|---|
| 投稿者 | Matera, Maria Gabriella; Calzetta, Luigino; De Biase, Alfredo; Lauro, Davide; Rogliani, Paola; Cazzola, Mario |
|---|
| 組織名 | Unit of Pharmacology, Department of Experimental Medicine, University of Campania;'Luigi Vanvitelli', Naples, Italy.;Unit of Respiratory Disease and Lung Function, Department of Medicine and;Surgery, University of Parma, Parma, Italy.;Unit of Endocrinology and Metabolic Diseases, Department of Systems Medicine,;University of Rome 'Tor Vergata', Rome, Italy.;Unit of Respiratory Medicine, Department of Experimental Medicine, University of;Rome 'Tor Vergata', Rome, Italy.;Rome 'Tor Vergata', Rome, Italy. Electronic address: mario.cazzola@uniroma2.it. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40614798/ |
|---|
